Official Title
Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
Brief Summary

A retrospective monocentric study with large active files of patients monitored for rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus with as main endpoint the morbimortality of Covid-19 in these patients (number of patients hospitalized in conventional units and/or in intensive care and/or deceased). The results will be compared with those of the general population based on the epidemiological data of Covid-19.

Terminated
SARS-COV2
Rheumatoid Arthritis
Rheumatic Diseases

Other: questionnaire assesment

15-minute face-to-face questionnaire

Eligibility Criteria

Inclusion Criteria:

- Patients with rheumatoid arthritis on conventional synthetic DMARD (csDMARDs) +/-
biological DMARD (bDMARDs) or targeted synthetic DMARD (tsDMARDs) +/- corticosteroid
therapy meeting ACR/EULAR 2010 classification criteria

- Patients with spondylarthritison biological DMARD or targeted synthetic DMARD +/-
conventional synthetic DMARD +/- non-steroidal anti-inflammatory drugs meeting ASAS
classification criteria

- Patients with systemic lupus erythematosus on hydroxychloroquine +/- conventional
synthetic DMARD +/- corticosteroid therapy +/- biological DMARD meeting ACR/EULAR 2019
classification criteria

Exclusion Criteria:

-

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Lille University Hospital
Lille, France

Jean-Guillaume Letarouilly, MD, Principal Investigator
University Hospital, Lille

University Hospital, Lille
NCT Number
Keywords
Immunotherapy
chronic inflammatory rheumatism
MeSH Terms
Rheumatic Fever
Rheumatic Diseases
Collagen Diseases